Pasithea Therapeutics - KTTA Aggregate Business Value
Pasithea Therapeutics (KTTA) develops medications to combat severe mental pathologies while minimizing the risks of raw material supply disruptions for testing. This chart confirms a market price of -32.64. The company protects its early-stage developments with patents, avoiding price wars in the race for schizophrenia treatments. The business relies on the opening of ketamine centers and the synthesis of new small molecules for the therapy of neurofibromatosis.
Pasithea Therapeutics Corp. - analytical breakdowns and key metrics (KTTA)
- current price and projected stock value:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
Debt to Capital Pasithea Therapeutics|KTTA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Pasithea Therapeutics Corp|KTTA - Company Debts|Debt to Net Assets Ratio Pasithea Therapeutics|KTTA - Company Long-Term Debt|Short-Term Debt Pasithea Therapeutics|Critical Liquidity Ratio pasitheaclinics.com
- business earnings and investment ratios data:
Analysis of all company metrics:Pasithea Therapeutics
Enterprise value reflects the total market price of an asset, combining market capitalization and debt minus liquid assets to assess the actual cost of acquisition. Analyzing the total capital level of Pasithea Therapeutics (KTTA) allows for a comparison of its financial stability against the resources of pharma behemoths, which is critical given the high risks and fierce competition involved in developing treatments for neurological pathologies.
Competitors of Pasithea Therapeutics (KTTA)
Aggregate Business Value BIIB (Biogen Inc)|NBIX: Real Price to Acquire Entire Company|Regencell Corp - Aggregate Business Value|AXSM: Enterprise Value|acadia-pharm.com (ACAD) - Enterprise Value|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value SUPN|CPRX - Total Enterprise Value|Denali Therapeutics - Real Price to Acquire Entire Company|Enterprise Value harmonybiosciences.com HRMY|BHVN - Total Company Value|Value Adjusted for Debt and Cash AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma (TRVI) - Total Company Value|Total Enterprise Value Praxis Corp (PRAX)|Total Company Value Anavex Life Sciences|ceribell.com - Full Business Value|Enterprise Value PRTA|Enterprise Value alector.com (ALEC)|Total Company Value Annexon Inc. ANNX|Company Buyout Price Omeros Corp (OMER)|Neurogene Inc. - Enterprise Value|Company Buyout Price acimmune.com ACIU|VYGR (Voyager Therapeutics, Inc.) - Real Price to Acquire Entire Company|NMRA: Aggregate Business Value|SCLX (Scilex Holding Co.) - Enterprise Value|TVGN: Value Adjusted for Debt and Cash|Enterprise Value ACOG|CGTX - Total Enterprise Value|Enterprise Value IKT (Inhibikase Therapeutics, Inc.)|Enterprise Value Cassava Sciences Inc SAVA|ASRT: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash COYA (Coya Therapeutics, Inc.)|VTGN (vistagen.com) - Real Price to Acquire Entire Company|OVID: Aggregate Business Value|ABOS (Acumen Pharmaceuticals, Inc.) - Enterprise Value|CRVO: Value Adjusted for Debt and Cash|Enterprise Value ATHE|CLNN - Total Enterprise Value|Total Company Value PepGen PEPG|Value Adjusted for Debt and Cash JUNS|Relmada Therapeutics, Inc. - Enterprise Value|ANVS - Enterprise Value|gracetx.com (GRCE) - Total Company Value|Full Business Value AIFF (Firefly Neuro)|KLTO (ANEW Medical) - Enterprise Value|Total Enterprise Value NeuroSense Therapeutics, Ltd. NRSN|Real Price to Acquire Entire Company RVPH (Reviva Pharmaceuticals Holdings, Inc.)|Enterprise Value metaviatx.com (MTVA)|NeurAxis, Inc - Real Price to Acquire Entire Company|Aggregate Business Value HSDT (Helius Medical Technologies, Inc.)|Passage Bio Corp - Enterprise Value|Company Buyout Price Neuphoria Therapeutics Inc. NEUP|NERV: Enterprise Value|Real Price to Acquire Entire Company Athira Pharma Inc|Total Company Value Addex Therapeutics, Ltd.|Alzamend (ALZN) - Company Buyout Price|Total Company Value Cyclerion Therapeutics (CYCN)|Enterprise Value protagenic.com (PTIX)|Cortigent - Real Price to Acquire Entire Company|Aggregate Business Value ATXI (Avenue Therapeutics Inc.)|BCLI: Real Price to Acquire Entire Company|Cara Therapeutics Inc - Aggregate Business Value|CHRO: Enterprise Value|Eliem Therapeutics Inc. (ELYM) - Enterprise Value|Total Company Value Intra-Cellular Therapies Inc.|Business Value LBPH (Longboard Pharmaceuticals Inc)|Enterprise Value MRNS|NKGN - Total Enterprise Value|NeuroBo Pharmaceuticals - Real Price to Acquire Entire Company|Enterprise Value sagerx.com SAGE|SNPX - Total Company Value|Value Adjusted for Debt and Cash TRVN (Trevena Inc.)|vigilneuro.com (VIGL) - Total Company Value|Total Enterprise Value anewmeds.com (WENA)|Total Company Value Cerevel Therapeutics